Pfizer Applications of Artificial Intelligence to Improve Speed / Precision of Treatment Selection and Clinical Management for Patients with Invasive Mold Infections
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire with unit
Memorial Deadline: Friday 10th, April 2026
External Deadline: Wednesday 15th, April 2026
Description
Pfizer External Research & Grants (ER&G) (formerly Global Medical Grants & Partnerships) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s ER&G competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.
For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.
Date RFP Issued: Feb 18, 2026
Geographic Scope: Australia, China, France, Germany, Italy, Spain, South Korea, Taiwan and the United Kingdom;
Proposals submitted by USA, Canada or Japan-based organizations for projects with a geographical scope aligned with the countries above and outside the USA, Canada or Japan will be considered.
Clinical Area: Invasive Mold Infections
Link to full RFP: 2026 II G IFI IME
Application Due Date: Apr 15, 2026
Specific Area of Interest: Potential applicants are requested to identify and address the educational needs, barriers and gaps for HCPs related to the application of artificial intelligence tools to integrate diagnostic stewardship and antifungal stewardship to improve speed and precision of treatment selection and to enhance clinical management for patients with invasive mold infections (IMIs), specifically Invasive Aspergillosis (IA) and Invasive Mucormycosis (IM).
Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Talita Honorato-Rzeszewicz (Talita.honorato-rzeszewicz@pfizer.com), with the subject line “2026 II G IFI IME”.